Fusion Pharmaceuticals Q2 EPS $(0.63) Up From $(2.99) YoY

Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.63) per share. This is a 78.93 percent increase over losses of $(2.99) per share from the same period last year.

byBill Haddad

August 10, 2021

1 minute read

Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.63) per share. This is a 78.93 percent increase over losses of $(2.99) per share from the same period last year.

Stifel Maintains Hold on Generac Hldgs, Lowers Price Target to $98

By Benzinga Newsdesk

Today, 2:37 AM

Stifel analyst Stephen Gengaro maintains Generac Hldgs (NYSE:GNRC) with a Hold and lowers the price target from $150 to $98.

GNRC

B of A Securities Downgrades Hewlett Packard to Neutral, Lowers Price Target to $16

By Benzinga Newsdesk

Today, 2:37 AM

B of A Securities analyst Wamsi Mohan downgrades Hewlett Packard (NYSE:HPE) from Buy to Neutral and lowers the price target from $19 to $16.

HPE

DXC Technology Statement; Says Due To The Financial Sponsor’s Challenges In Raising The Necessary Capital, As A Result Of Current Market Conditions, No Formal Proposal Was Received By The Company And DXC Has Terminated The Discussions

By Happy Mohamed

Today, 2:37 AM

In response to market rumors and speculation, on Oct 4th, 2022, DXC Technology (NYSE:DXC) announced that it was approached by a financial sponsor regarding a potential acquisition of the company. Consistent with its

DXC